Ruti Aga banned for six years: forged prescription by a family member, and a glucocorticoid case that ended a career

Ethiopian marathon runner Ruti Aga has been banned for six years by the Athletics Integrity Unit (AIU). The sanction is built from two separate violations in the same case: two years for the presence of methylprednisolone in a sample taken after a half marathon in China in March, and four years for tampering with the investigation through a fabricated document and misleading statements. The AIU announced the outcome in a statement issued on Thursday. According to the AIU, Aga was provisionally suspended from 10 September, and the six-year period is dated from the same day. The practical consequence is stark: a 32-year-old athlete will not be eligible to compete again until she is roughly 38. In elite women's marathon running, that is not a comeback age - it is a retirement age. The race that produced the sample was a half marathon in China, and Aga won it. The statement gives no time, no splits and no field description, so no performance judgement is possible from the source material. The substance: a glucocorticoid, not a steroid The most important technical point in this case is also the one most widely misreported. Methylprednisolone is not an anabolic steroid. It is a glucocorticoid, sitting in class S9 of the WADA Prohibited List; anabolic steroids are class S1. The distinction is not semantic - it changes the entire legal direction of the case. Under the current List, S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal routes. A therapeutic knee injection administered out-of-competition is entirely lawful; it becomes a violation only if residues are still present in an in-competition sample. In road running the testing window opens at 23:59 on the day before the race, which means an injection given days earlier can still be caught. The implication is that Aga had a legitimate defence available: prove the date, the route and the medical necessity of the treatment. It is also worth stating plainly that glucocorticoids have no established endurance-performance benefit, so describing this as a performance-enhancing case in the ordinary sense is imprecise. The two-plus-four arithmetic Read the structure of the sanction and it is standard, not exceptional. Two years for the presence violation is consistent with a finding involving a Specified Substance where intent was not established. Four years for tampering is the Code's standard sanction. Added together: six years. The arithmetic tells us something specific. The panel declined the no-significant-fault mitigation that would normally have reduced the presence sanction. In other words, the forged prescription did not merely create a second charge; it eliminated the room for a defence on the first. There is a mild paradox here: forged documentation is itself circumstantial evidence of an intent to conceal, yet it did not aggravate the presence sanction - it was placed on a separate limb entirely. One forged prescription, three verification failures Aga's explanation was that she received methylprednisolone to treat a knee injury. The documentation failed at three independent levels. First, the clinic named on the prescription did not exist. Second, the person who presented himself as the doctor was a family member with no medical registration. Third, that person claimed to have used an old prescription pad from a former workplace - a claim the institution in question explicitly disowned. Three verification checks, three failures. This was not a filing error. It is the signature of an athlete operating without a credentialed team physician at all. A properly managed athlete with a documented knee injection would either hold a Therapeutic Use Exemption or apply for one, or would observe WADA's route-specific washout period. None of that appears to have happened. The knee injury: the real root cause The injury explanation is mechanically plausible. Intra-articular or peri-articular glucocorticoid injection for knee synovitis is standard sports-medicine practice in distance runners. But that plausibility is exactly what makes the case worse: if the treatment had genuinely occurred and records existed, real records would have been produced. A forgery is evidence that the documented treatment did not exist. There is a systemic signal here too. Marathoners face intense pressure to keep racing through injury because appearance fees make up a large share of income. Glucocorticoids are the cheapest and most available tool for masking pain. And where the surrounding medical network is informal, documents get invented. It is also possible that the knee problem was chronic and career-long rather than an acute March event - manufacturing a paper trail suggests a repeated pattern of informal treatment, not a single lapse. The career arithmetic Aga is 32, positioned at late peak or the beginning of decline on the age curve. Public records put her best at around 2:18:34 in Berlin 2026, where she finished second, and she won the 2026 Tokyo Marathon. She also holds three second-place finishes at World Marathon Majors. The AIU statement itself does not list a personal best, so those figures come from external records. It matters that the disqualification scope is not automatically limited to the race where the sample was collected. Standard AIU practice voids the result and prize money from that competition, and ranking points accrued after that date go with it. Results from before the violation, including the 2026 Tokyo title, are not automatically annulled absent a finding of earlier use. The AIU statement does not specify the disqualification scope, which is a genuine gap in the reporting. Almost no effect on the competitive landscape Ethiopia's women's marathon depth is such that a 2:18 performer is not automatically selectable for a national team. The removal of one athlete is effectively invisible at national-team level. Kenya is equally deep. Both countries share the same structural problem: extreme depth paired with very thin oversight of the entourage around the athlete. Aga's three Major runner-up finishes were commercial-tier results, not global championship medals, so her absence does not shift Ethiopia's medal capacity by any measurable margin. That is why this case should be read as a governance story rather than a competition story. What is changing is that AIU enforcement has moved beyond detection into document verification. And the clustering of cases in which an initial substance violation is compounded by a fabricated or altered explanation suggests this is not an isolated incident. The Chinese label-race circuit The March race took place in China and Aga won it, which implies a staged international event with out-of-competition or in-competition testing. For East African marathoners, the Chinese and wider Asian label-race circuit has functioned as a lucrative, relatively low-risk income tier between Majors - few races, high appearance fees. That same tier is now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding in the same races, and the cost of that collision falls first on the athletes with the least legal and institutional support. What a competent defence would have achieved There were three routes. First, real medical records showing the injection was administered sufficiently before competition that no residue could remain. Second, a Therapeutic Use Exemption application where medical necessity was clear. Third, a documented history of knee treatment supporting a no-significant-fault argument. None of the three was used. The result is that a case which might plausibly have ended in a reprimand or a short suspension became a six-year ban. That is the harshest lesson here: the substance outcome was not the worst-case scenario - the method chosen to avoid it was. Appeal prospects A reasoned decision normally opens an appeal window of around 21 days to the Court of Arbitration for Sport. But a document-based tampering finding is hard to overturn, because it rests on evidence rather than interpretation. Three independent verification failures narrow the route considerably. The appeal risk is live but of low practical value. The proportionality debate A six-year ban for a substance with no proven endurance benefit will be argued over. One side will read it as proof of AIU rigour and zero tolerance for documentary fraud. The other will read it as inconsistent enforcement against East African road runners. What that debate usually misses is that the larger share of the six years is for the document, not the substance. Holding that distinction matters, otherwise glucocorticoid cases get weighed on the same scale as anabolic-steroid cases, which is factually wrong. It also means that reports describing this as a 'steroid' case are misleading on both technical and legal grounds. The entourage question The AIU statement names only the family member who produced the prescription. It is not clear whether the role of any agent, manager or coach was investigated. That gap matters, because a 32-year-old elite athlete rarely decides alone to manufacture such a document and place it before anti-doping investigators. Language and translation in AIU interviews are also a recurring point of contention. The four-year tampering sanction flowed not only from a document but from statements made under questioning. The availability of legal support and the conditions of those interviews should form part of the scrutiny. Commercial impact Aga's record - the 2026 Tokyo title and three Major second places - is the record of a genuinely elite marathoner and will stand historically, because the violation is anchored to a later race. But after a six-year ban her commercial value in the sponsorship market is close to zero, and distance-running sponsorship is already thin. Six years is, in functional terms, a lifetime ban: there is no realistic return pathway at 38. Conclusion This case should be read on two levels. On the individual level: a knee injury, an informal medical network, a forged prescription, and then six years - a self-inflicted outcome that converted what might have been a two-year absence into the end of a career. On the systemic level: until athletes have access to credentialed physicians, TUE infrastructure and clear guidance, these cases will repeat. AIU rigour alone cannot close that gap - it can only catch the people who fall into it.